Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sanara MedTech Inc.WNDM · Entity 5880 | Director | February 27, 2017 | April 04, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sanara MedTech Inc.
Report date February 27, 2017 · Filed April 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,000 |
Reported balance
After 2017-02-27 transaction · row 1
1 source rowRow 1 · 2017-02-27 · Grant · Acquired 150,000 · Balance 500,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2017 Filed Apr 4, 2017 00:34 UTC | Sanara MedTech Inc. WNDM · Entity 5880 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001574181-17-000001 · primary_doc.xml · nonDerivative · entry 1 Rubinfeld Philip J · CIK 0001574181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.